HOME >> BIOLOGY >> NEWS
Women are more likely to suffer recurrent miscarriages if their first child is a boy

Madrid, Spain: Women who give birth to a boy as their first child are more likely to suffer subsequent miscarriages than women whose first baby is a girl, an international conference of fertility experts heard today (Tuesday 1 July).

Dr Ole Christiansen, a consultant registrar at the Rigshospitalet Fertility Clinic in Copenhagen, Denmark, told the annual conference of the European Society of Human Reproduction and Embryology, that giving birth to a boy first was not only a risk factor for subsequent miscarriages, but for women who suffered unexplained secondary recurrent miscarriages (SRM) it could mean that they never managed to carry a child to full term again unless doctors gave them appropriate treatments.

Dr Christiansen said: "Giving birth to a son is known already to be a prognostically negative factor in many obstetrical complications. Therefore we wanted to assess the impact of the gender of the first child on the outcome of subsequent pregnancies among patients with unexplained secondary recurrent miscarriages.[1]"

He studied 204 SRM patients admitted to clinics between 1986 and 2000, and obtained information on subsequent pregnancy outcome in 181 patients admitted before 2000. Among the patients admitted before 2000, only 54.4% of those who gave birth to a boy in their first pregnancy had given birth to a second live baby by January 2002, compared with 73% of women whose first child was a girl.

Amongst a subset of women who did manage to have a second child after a series of miscarriages, those whose first child was a boy had an average of 3.9 miscarriages before achieving a second birth, while women whose first child was girl had 3.5 miscarriages before delivery of a second child a small but statistically significant difference. Average birth weights of the second children tended to be 181g higher where the first-born was a girl.

Dr Christiansen said: "Our study shows that the majority (54.4%) of those
'"/>

Contact: Emma Mason
wordmason@aol.com
44-0-1376-563090
European Society for Human Reproduction and Embryology
1-Jul-2003


Page: 1 2 3

Related biology news :

1. Women who have donated eggs sought for national study
2. Donaghue Womens Health Investigator Program awards grants to three at Yale
3. Top Houston Women in Technology honoree at UH
4. Marie Curie Nobel Centennial Celebration of Women in Science
5. Victoria Hale of Institute for OneWorld Health Named Fellow by International Womens Forum
6. Women who drink may be at greater risk of cardiovascular complications than men
7. Jefferson and Brigham and Womens researchers find blue light important for setting biological clock
8. Womens health issues, child and adolescent disorders featured at APAs annual meeting
9. Women who marry alcoholics
10. Pregnancy hormone induces healthy blood vessels, Magee-Womens Research Institute scientists report
11. US Women scientists from Latin America to encourage colleagues from south

Post Your Comments:
(Date:10/16/2014)... Cancer constantly wages war on the human body. ... a stalemate. In pancreatic cancer, this stalemate—known as ... becoming aggressively malignant, a phenomena that is poorly ... in the laboratory of Salvatore Torquato, a Professor ... the conditions surrounding tumor dormancy and the switch ...
(Date:10/16/2014)... cultivated efficiently, they are anything but sustainable: environmental ... cultivation is becoming increasingly evident. Despite their disadvantages, ... are regarded as the sole possibility of achieving ... finds Bernhard Schmid, an ecology professor at the ... of agriculture and forestry. After all, a new ...
(Date:10/15/2014)... , Oct. 15, 2014 Sandata Technologies, ... home and community-based care, today announced it released ... Sandata,s Santrax® Electronic Visit Verification™ Solution (EVV™)  for ... a home health company founded in 1996 and ... . The study details the ...
Breaking Biology News(10 mins):Modeling tumor dormancy 2Plant communities produce greater yield than monocultures 2Plant communities produce greater yield than monocultures 3Sandata Announces Case Study with Quality Care Services, Inc. 2
(Date:10/22/2014)... , Oct. 22, 2014 Nuvilex, Inc. ... approximately 400 million people worldwide are living with diabetes, ... people by 2030.  The global market for diabetes treatments ... approximately 330,000 people worldwide died from pancreatic cancer.  Pancreatic ... due to cancer in the United States ...
(Date:10/20/2014)... The report “Pharmacy Automation Systems Market ... Labeling Systems, Table-top Counters) by End-user (Inpatient Pharmacy ... Trends to 2019” analyzes and studies the major ... Europe, Asia-Pacific, and the Rest of the World ... figures spread through 300 pages and in-depth TOC ...
(Date:10/20/2014)... PARK, Calif. , Oct. 20, 2014 /PRNewswire/ ... today that the Company has signed a Notice ... of Regenerative Medicine (CIRM), effective October 1, 2014.  ... Clinical Development payments and the release of additional ... million CIRM grant award for clinical development of ...
(Date:10/20/2014)... Md. , Oct. 20, 2014  GenVec, Inc. (NASDAQ: ... Zola P. Horovitz , Ph.D., from its board of directors ... board in August 2003, and served as its chairman from ... served on the Nominating and Corporate Governance and Audit Committees ... for more than a decade of dedicated service to GenVec, ...
Breaking Biology Technology:Nuvilex Brief Analyst Report: Thinking Outside the Box by BrokerBank Securities, Inc. 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 2Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 3Pharmacy Automation Systems Market worth $4,566.2 Million by 2019 - New Research Report by MarketsandMarkets 4Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 2Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 3Asterias Biotherapeutics Announces Notice of Grant Award with CIRM for Phase 1/2a Clinical Trial of AST-OPC1 in Complete Cervical Spinal Cord Injury 4Zola P. Horovitz To Retire From GenVec Board 2
Cached News: